This is a preview of subscription content, log in via an institution to check access.
References
Go A, et al Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation. 2014;129:e28-292.
Yancy CW, et al ACCF/AHA guideline for the management of heart failure. Circulation. 2013;128:e240-327.
Moss AJ, et al Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 1996;335:1933-40.
Moss AJ, et al Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877-83.
Bardy GH, Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators, et al Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225-37.
Buxton AE, et al A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 1999;341:1882-90.
Bigger JT Jr. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. N Engl J Med. 1997;337:1569-75.
Hohnloser SH, DINAMIT Investigators, et al Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med. 2004;351:2481-8.
Steinbeck G, IRIS Investigators, et al Defibrillator implantation early after myocardial infarction. N Engl J Med. 2009;361:1427-36.
Kadish A, Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators, et al Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350:2151-8.
Vollmann D, Luthje L, Vonhof S, Unterberg C. Inappropriate therapy and fatal proarrhythmia by an implantable cardioverter-defibrillator. Heart Rhythm. 2005;2:307-9.
Mark DB, Anstrom KJ, Sun JL. Quality of life with defibrillator therapy or amiodarone in heart failure. N Engl J Med. 2008;359:999-1008.
Kremers MS, et al The National ICD Registry Report: version 2.1 including leads and pediatrics for years 2010 and 2011. Heart Rhythm. 2013;10:e62.
Passman R, et al Predicting the future: risk stratification for sudden cardiac death in patients with left ventricular dysfunction. Circulation. 2012;125:3031-7.
Voigt A, Shalaby A, Saba S. Rising rates of cardiac rhythm management device infections in the United States: 1996 through 2003. J Am Coll Cardiol. 2006;48:590-1.
Uslan DZ, Sohail MR, St Sauver JL, et al Permanent pacemaker and implantable cardioverter defibrillator infection: a population-based study. Arch Intern Med. 2007;167:669-75.
Sohail MR, Uslan DZ, Khan AH, et al Risk factor analysis of permanent pacemaker infection. Clin Infect Dis. 2007;45:166-73.
Baddour L, Heart Rhythm Society, et al Update on cardiovascular implantable electronic device infections and their management. a scientific statement from the American Heart Association. Circulation. 2010;121:458-77.
Jacobson AF, et al Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) Study. J Am Coll Cardiol. 2010;55:2212-21.
Tamaki S, Yamada T, Okuyama Y, Morita T, Sanada S, Tsukamoto Y, et al Cardiac iodine-123 metaiodobenzylguanidine imaging predicts sudden cardiac death independently of left ventricular ejection fraction in patients with chronic heart failure and left ventricular systolic dysfunction: results from a comparative study with signal-averaged electrocardiogram, heart rate variability, and QT dispersion. J Am Coll Cardiol. 2009;53:426-35.
Nagarahara D, Nakata T, Hashimoto A. Predicting the need for an implantable cardioverter defibrillator using cardiac metaiodobenzylguanidine activity together with plasma natriuretic peptide concentration or left ventricular function. J Nucl Med. 2008;49:225-33.
Agostini D, Verberne HJ, Burchert W, Knuuti J, Povinec P, Sambuceti G, et al I-123-mIBG myocardial imaging for assessment of risk for a major cardiac event in heart failure patients: insights from a retrospective European multicenter study. Eur J Nucl Med Mol Imaging. 2008;35:535-46.
Nakata T, Nakajima K, Yamashina S, Yamada T, Momose M, Kasama S, et al A pooled analysis of multicenter cohort studies of (123) I-mIBG imaging of sympathetic innervation for assessment of long-term prognosis in heart failure. JACC Cardiovasc Imaging. 2013;6:772-84.
GE Healthcare AdreView™ Iobenguane I 123 Injection Prescibing Information. 2013. Accessed at http://www3.gehealthcare.com/.../adreview/gehealthcare_adreview-prescribing-information.pdf.
Disclosure
Dr. M. I. Travin reports he is retained on Speakers’ Bureau by GE Healthcare. Dr. A. E. Buxton reports research grants from Biosense-Webster. Dr. A. E. Buxton has also received support for an investigator initiated study from Medtronic. Dr. R. Doukky reports an investigator initiated grant from Astellas Pharmaceuticals. He also serves on an advisory board for Astellas. D. A. Merlino is a consultant for the American Society of Nuclear Cardiology, the Society of Nuclear Medicine and Molecular Imaging, Bracco, the United Pharmacy Partners, and CIS-US now Pharmalucence. Other authors have reported nothing to disclose in relation to this topic and review.
Rights and permissions
About this article
Cite this article
Sciammarella, M.G., Gerson, M., Buxton, A.E. et al. ASNC/SNMMI Model Coverage Policy: Myocardial sympathetic innervation imaging: Iodine-123 meta-iodobenzylguanidine (123I-mIBG). J. Nucl. Cardiol. 22, 804–811 (2015). https://doi.org/10.1007/s12350-015-0202-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12350-015-0202-8